The expression levels of telomerase catalytic subunit hTERT and oncogenic MYC in essential thrombocythemia are affected by the molecular subtype

Annals of Hematology

Volumn 87, Issue 4, 2008, Pages 263-268

  Theophile, Katharina ^a   Buesche, Guntram ^a   Kreipe, Hans ^a   Bock, Oliver ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Essential thrombocythemia; hTERT; JAK2; MYC; Myeloproliferative disorder; Telomerase

Indexed keywords

JANUS KINASE 2; MYC PROTEIN; PHENYLALANINE; TELOMERASE REVERSE TRANSCRIPTASE; VALINE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVE SITE; FEMALE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; ONCOGENE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTHEMIA; UPREGULATION;

ADULT; AGED; AMINO ACID SUBSTITUTION; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENES, MYC; HUMANS; JANUS KINASE 2; LEUKEMIA; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 41249102333     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0424-1     Document Type: Article

References (25)

1. Boukamp P (2001) Ageing mechanisms: The role of telomere loss. Clin Exp Dermatol 26:562-565
2. Bailey SM, Murnane JP (2006) Telomeres, chromosome instability and cancer. Nucleic Acids Res 34:2408-2417
3. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
4. Blackburn EH (2001) Switching and signaling at the telomere. Cell 106:661-673
5. Cech TR (2004) Beginning to understand the end of the chromosome. Cell 116:273-279
6. Norrback KF, Roos G (1997) Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 33:774-780
7. Ducrest AL, Amacker M, Mathieu YD, Cuthbert AP, Trott DA, Newbold RF, Nabholz M, Lingner J (2001) Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res 61:7594-7602
8. Rudolph KL, Millard M, Bosenberg MW, DePinho RA (2001) Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28:155-159
9. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791
10. Brümmendorf TH, Balabanov S (2006) Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 20:1706-1716
11. Hartmann U, Brümmendorf TH, Balabanov S, Thiede C, Illme T, Schaich M (2005) Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 90:307-316
12. Terasaki Y, Okumura H, Ohtake S, Nakao S (2002) Accelerated telomere length shortening in granulocytes: A diagnostic marker for myeloproliferative diseases. Exp Hematol 30:1399-1404
13. Ferraris AM, Mangerini R, Pujic N, Racchi O, Rapezzi D, Gallamini A, Casciaro S, Gaetani GF (2005) High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood 105:2138-2140
14. Altshuler ML, Severin SE, Glukhov AI (2003) The tumor cell and telomerase. Biochemistry (Mosc) 68:1275-1283
15. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21:220-224
16. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, DePinho RA (1999) Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-1226
17. Cerni C (2000) Telomeres, telomerase, and myc. An update. Mutat Res 462:31-47
18. Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J (2006) hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 20:671-679
19. Lehmann U, Kreipe H (2001) Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 25:409-418
20. Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O (2007) Different involvement of the megakaryocytic lineage by the JAK2(V617F) mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Ann Hematol 86:245-253
21. Bièche I, Noguès C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M (2000) Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:452-459
22. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
23. Xie S, Lin H, Sun T, Arlinghaus RB (2002) Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 21:7137-7146
24. Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL (2005) The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 106:2862-2864
25. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366:1945-1953